This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on july 25, 2017.(b)(4).Visual inspection was performed on the returned sample, during which no anomalies were noted anywhere on the device.Ops valves are subject to a 100% leak test, which includes five different tests the units are run through to ensure there are no leaks and both the umbrellas and duckbills are functioning properly.The returned sample was manually run through each of these tests and passed' the returned sample was found to function as intended, and met all of the product specifications.There is a known issue currently ongoing with the duckbill valve within the ops valve, that prevents the duckbill from opening within the product specification range.It is possible that the duckbill valve did not open during the reported event; however, if a high enough pressure had been reached after that initial attempt, the seal in the slit of the duckbill may have been broken, or over time the slit had re-opened, allowing the device to pass all leak tests during the evaluation of the returned sample.This was not able to be confirmed.The cause of the issue with the duckbill is due to a process change at the supplier, specifically during the washing/cleaning step; however, the investigation for this is ongoing.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|